These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 8906290)
1. A comparative study of tissue distribution and excretion among three substances implicated in eosinophilia-myalgia syndrome. Adachi J; Ueno Y; Tatsuno Y; Gomez M; Smith CC; Sternberg EM Adv Exp Med Biol; 1996; 398():365-70. PubMed ID: 8906290 [No Abstract] [Full Text] [Related]
2. Identification of four metabolites of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in rats. Adachi J; Mio T; Ueno Y; Naito T; Nishimura A; Fujiwara S; Sumino K; Tatsuno Y Arch Toxicol; 1994; 68(8):500-5. PubMed ID: 7802590 [TBL] [Abstract][Full Text] [Related]
3. Accumulation of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in blood and organs of the Lewis rats. Adachi J; Gomez M; Smith CC; Sternberg EM Arch Toxicol; 1995; 69(4):266-70. PubMed ID: 7755488 [TBL] [Abstract][Full Text] [Related]
4. Accumulation of 1-methyl-tetrahydro-beta-carboline-3-carboxylic acid in blood and organs of rat. A possible causative substance of eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan. Ogawa Y; Adachi J; Tatsuno Y Arch Toxicol; 1993; 67(4):290-3. PubMed ID: 8517786 [TBL] [Abstract][Full Text] [Related]
5. Effects of tryptophan related compounds on nuclear regulatory control. Possible role in the eosinophilia-myalgia syndrome. Sidransky H; Verney E; Latham P; Schwartz A Adv Exp Med Biol; 1996; 398():343-50. PubMed ID: 8906287 [No Abstract] [Full Text] [Related]
6. Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome. Sato F; Hagiwara Y; Kawase Y Arch Toxicol; 1995; 69(7):444-9. PubMed ID: 8526739 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and analysis of contaminants in ems-related tryptophan. Steinhart H; van Wickern B; Meyer K; Simat T Adv Exp Med Biol; 1996; 398():667-75. PubMed ID: 8906342 [No Abstract] [Full Text] [Related]
8. Metabolism and distribution in the rat of peak E substance, a constituent in L-tryptophan product implicated in eosinophilia-myalgia syndrome. Adachi J; Naito T; Ueno Y; Ogawa Y; Ninomiya I; Tatsuno Y Arch Toxicol; 1993; 67(4):284-9. PubMed ID: 8517785 [TBL] [Abstract][Full Text] [Related]
9. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome? Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924 [TBL] [Abstract][Full Text] [Related]
10. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro. Zangrilli JG; Mayeno AN; Vining V; Varga J Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499 [TBL] [Abstract][Full Text] [Related]
11. 1,1'-Ethylidenebis[tryptophan] induces pathologic alterations in muscle similar to those observed in the eosinophilia-myalgia syndrome. Emslie-Smith AM; Mayeno AN; Nakano S; Gleich GJ; Engel AG Neurology; 1994 Dec; 44(12):2390-2. PubMed ID: 7991132 [TBL] [Abstract][Full Text] [Related]
12. Endogenous formation of 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3- carboxylic acid in man as the possible causative substance of eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan. Adachi J; Yamamoto K; Ogawa Y; Ueno Y; Mizoi Y; Tatsuno Y Arch Toxicol; 1991; 65(6):505-9. PubMed ID: 1929872 [TBL] [Abstract][Full Text] [Related]
13. Identification of decomposition products of 1,1'-ethylidenebis [L-tryptophan], a compound associated with eosinophilia-myalgia syndrome. Driskell WJ; Ashley DL; Grainger J; Sirimanne SR; Mazzola EP; Page SW; Needham LL; Hill RH Bull Environ Contam Toxicol; 1992 May; 48(5):679-87. PubMed ID: 1504513 [No Abstract] [Full Text] [Related]
14. Biotechnology. Yellow light on L-tryptophan. Aldhous P Nature; 1991 Oct; 353(6344):490. PubMed ID: 1922349 [No Abstract] [Full Text] [Related]
15. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico. Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958 [TBL] [Abstract][Full Text] [Related]
16. Animal models of the eosinophilia-myalgia syndrome. Clauw DJ J Rheumatol Suppl; 1996 Oct; 46():93-7; discussion 92, 97-8. PubMed ID: 8895185 [TBL] [Abstract][Full Text] [Related]
17. Delayed onset of skin fibrosis after the ingestion of eosinophilia-myalgia syndrome-associated L-tryptophan. Greenberg AS; Takagi H; Hill RH; Hasan A; Murata H; Falanga V J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):264-6. PubMed ID: 8708033 [No Abstract] [Full Text] [Related]
18. Production of polyclonal antibodies against 1,1'-ethyliden bis[L-tryptophan] (EBT), a potential contaminant causing eosinophilia-myalgia syndrome (EMS). Kurihara N; Yanagisawa H; Jin Z; Wada O Toxicol Lett; 1993 Mar; 66(3):231-6. PubMed ID: 8475503 [TBL] [Abstract][Full Text] [Related]